OVID - Ovid Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.8800
+0.0600 (+3.30%)
As of 12:11PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.8200
Open1.8300
Bid1.8600 x 1000
Ask1.8900 x 800
Day's Range1.7750 - 1.9000
52 Week Range1.5300 - 11.4500
Volume75,924
Avg. Volume576,328
Market Cap70.345M
Beta (3Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire8 days ago

    Ovid Therapeutics to Host R&D Day on June 27, 2019

    NEW YORK, June 18, 2019 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium
    PR Newswirelast month

    Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium

    NEW YORK, May 23, 2019 /PRNewswire/ -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, will present data on safety, tolerability, exploratory and secondary outcomes from the Phase 1b/2a clinical trial of OV935/TAK-935 in adult patients with developmental and epileptic encephalopathies (DEE). The data will be presented as a poster at the 12th International Epilepsy Colloquium (IEC), taking place May 26-28 in Lyon, France.

  • GlobeNewswire2 months ago

    Ovid Therapeutics Reports First Quarter 2019 Financial Results

    Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN Top Science Press.

  • GlobeNewswire2 months ago

    Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting

    Ovid Therapeutics Inc. (OVID) continues to build on its neuroscience research platform with the presentation of data from the OV101 (gaboxadol) investigational program for rare neurodevelopmental conditions.  Ovid’s presentations on Angelman syndrome and Fragile X syndrome are part of the program at the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia (May 4 - 10). “Ovid’s research efforts are focused on finding treatments for rare diseases, which are defined in the US as conditions affecting fewer than 200,000 people, and specifically, we seek to improve the lives of the approximately 8 million people in the US alone living with neurologic manifestations of rare diseases1,” said Amit Rakhit, MD, MBA, Chief Medical Officer and Head of Research & Development at Ovid.

  • GlobeNewswire3 months ago

    Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced changes to its senior management team to focus the company’s resources and attention on its late stage pipeline. Amit Rakhit, M.D., MBA, is adding the role of Head of R&D to his current position as Chief Medical Officer. As part of this transition, Dr. During has decided not to stand for reelection following his current term on Ovid’s Board of Directors.

  • GlobeNewswire3 months ago

    Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced the appointment of Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary. Mr. Perone is succeeding Ana Ward who will be leaving the Company. “We are delighted to welcome Tom to Ovid,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.

  • GlobeNewswire4 months ago

    Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

    NEW YORK, March 07, 2019 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • GlobeNewswire4 months ago

    Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11

    NEW YORK, March 04, 2019 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

  • GlobeNewswire4 months ago

    Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the pricing of underwritten public offerings of (i) 12,500,000 shares of its common stock and (ii) 2,500 shares of its non-voting Series A Convertible Preferred Stock (“Series A stock”) (together, the “Offerings”). The public offering price of each share of common stock is $2.00 and the public offering price of each share of Series A stock is $2,000.00. In addition, Ovid Therapeutics has granted the underwriters a 30-day option to purchase additional shares of common stock of up to 15% of the number of shares offered in the common stock offering.

  • GlobeNewswire4 months ago

    Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock (“Series A stock”) in two concurrent but separate underwritten public offerings. Neither of the proposed common stock offering or the Series A stock offering (together, the “Offerings”) are contingent upon the consummation of the other. Cowen and Company, LLC and William Blair & Company, L.L.C. are acting as joint book-running managers for the Offerings.

  • GlobeNewswire6 months ago

    Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced results from a 12-week, Phase 1b/2a clinical trial of OV935/TAK-935 that enrolled 18 adults with rare developmental and epileptic encephalopathies (DEE) who were not successfully treated with available treatment regimens. The trial achieved its primary endpoint of safety and tolerability and showed OV935 was generally well tolerated. Exploratory analysis of OV935 showed reduction in seizure frequency that was correlated with decreases in plasma 24-hydroxycholesterol (24HC) levels in adults across multiple DEE.

  • GlobeNewswire7 months ago

    Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced plans to move ahead with a single pivotal Phase 3 trial of OV101 in pediatric patients with Angelman syndrome based on its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). If successful, the Phase 3 efficacy and safety trial called NEPTUNE is intended to support a New Drug Application (NDA) for OV101 in Angelman syndrome.

  • GlobeNewswire7 months ago

    Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present two poster presentations and one oral presentation on OV935/TAK-935 at the American Epilepsy Society (AES) 72nd Annual Meeting, taking place from November 30 – December 4, 2018, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. “The oral presentation will report new preclinical work in a genetic seizure model – the Dravet syndrome mouse model – showing OV935’s potential impact on seizure incidence, frequency and severity and improvement in overall survival,” said Matthew During, M.D., D.Sc., founder and chief scientific officer of Ovid Therapeutics.

  • GlobeNewswire7 months ago

    Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 11:00 a.m. EST. The conference will be held at the Lotte New York Palace. Ovid Therapeutics (OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders.

  • GlobeNewswire8 months ago

    Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported financial results for the third quarter ended September 30, 2018 and recent progress in its clinical programs. “The remaining two months of 2018 will be an active period for Ovid,” said Jeremy Levin, DPhil, MB, BChir, chairman and chief executive officer of Ovid Therapeutics. “We will meet with the FDA to discuss the next steps for OV101 in Angelman syndrome.